

1. REVLIMID [package insert]. Summit, NJ: Celgene Corp; 2019.
2. American Cancer Society. Key statistics for myelodysplastic syndromes. www.cancer.org/cancer/myelodysplastic-syndrome/about/key-statistics.html. Updated January 22, 2018. Accessed September 24, 2019.
3. Rojas SM, Díez-Campelo M, Luno E, et al. Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis. *Leuk Res*. 2014;38:304-309.
4. Kurtin SE. Advances in the management of low- to Intermediate-risk myelodysplastic syndrome: integrating the National Comprehensive Cancer Network Guidelines. *Clin J Oncol Nurs*. 2006;10(2):197-208.
5. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myelodysplastic Syndromes V.1.2020. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed October 18, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org. The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
6. Adès L, Itzykson R, Fenaux P. Myelodysplastic syndromes. *Lancet*. 2014;383(9936):2239-2252.
7. Bejar R, Steensma DP. Recent developments in myelodysplastic syndromes. *Blood*. 2014;124(18):2793-2803.
8. Foran JM, Shammo JM. Clinical presentation, diagnosis, and prognosis of myelodysplastic syndromes. *Am J Med*. 2012;125(7 suppl):S6-S13.
9. Varney ME, Melgar K, Niederkorn M, Smith M, Barreyro L, Starczynowski DT. Deconstructing innate immune signaling in myelodysplastic syndromes. *Exp Hematol*. 2015;43(8):587-598.
10. Steensma DP, Heptinstall KV, Johnson VM, et al. Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey. *Leuk Res*. 2008;32(5):691-698.

11. Beris P, Georgiou G. Overview of myelodysplastic syndromes. *Semin Hematol*. 2012;49(4):287-294.
12. Bates I, Burthem J. Bone marrow biopsy. In: *Darcie and Lewis Practical Haematology, 12th edition*. 2017;112-125. New York, NY: Elsevier.
13. Heaney ML, Golde DW. Myelodysplasia. *N Engl J Med*. 1999;340(21):1649-1660.
14. Gibson CJ, Ebert BL, Steensma DP. Myelodysplastic syndromes. In: *Hematology: Basic Principles and Practice, 7th edition*. 2018;944-969. New York, NY: Elsevier.
15. Haase D, Germing U, Schanze J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2114 patients. *Blood*. 2007;110(13):4385-4395.
16. Mallo M, Luño E, Sanzo C, et al. Clinical impact of the clone size in MDS cases with monosomy 7 or 7q deletion, trisomy 8, 20q deletion and loss of Y chromosome. *Leuk Res*. 2011;35:834-836.
17. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. *Blood*. 1997;89(6):2079-2088.
18. Data on file. Celgene Corporation. Summit, NJ.
19. List AF, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. *N Engl J Med*. 2006;355(14):1456-1465.
20. List AF, Bennett JM, Sekeres MA, et al. Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS. *Leukemia*. 2014;28(5):1033-1040.
21. Chen N, Lau H, Kong L, et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. *J Clin Pharmacol*. 2007;47(12):1466-1475.
22. National Kidney Foundation. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *KI Suppl*. 2013;3(1):1-150. For additional information regarding renal guidelines please refer to the National Kidney Foundation website.
23. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron*. 1976;16(1):31-41.

